作者
Daniel P Petrylak, Robert B Macarthur, John O'Connor, Gary Shelton, Timothy Judge, Joshua Balog, Charles Pfaff, Emilia Bagiella, Daniel Heitjan, Robert Fine, Nancy Zuech, Ihor Sawczuk, Mitchell Benson, Carl A Olsson
发表日期
1999/3
期刊
Journal of clinical oncology
卷号
17
期号
3
页码范围
958-958
出版商
American Society of Clinical Oncology
简介
PURPOSE: To evaluate the toxicity, efficacy, and pharmacokinetics of docetaxel when combined with oral estramustine and dexamethasone in a phase I study in patients with progressive metastatic androgen-independent prostate cancer.
PATIENTS AND METHODS: Thirty-four men were stratified into minimally pretreated (MPT) and extensively pretreated (EPT) groups. Estramustine 280 mg PO tid was administered 1 hour before or 2 hours after meals on days 1 through 5, with escalated doses of docetaxel from 40 to 80 mg/m2 on day 2. Treatment was repeated every 21 days.
RESULTS: Thirty-four patients were assessable for toxicity and 33 for response. In the MPT patients, dose-limiting myelosuppression was reached at 80 mg/m2, with six patients experiencing grade 3/4 granulocytopenia. In EPT patients, escalation above 70 mg/m2 was not attempted. Fourteen MPT (70%) and six EPT (50%) patients …
引用总数
学术搜索中的文章
DP Petrylak, RB Macarthur, J O'Connor, G Shelton… - Journal of clinical oncology, 1999